title: Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma.
abstract: BACKGROUND
  The aim of this study was to develop, validate and compare flow injection analysis (FIA) and ultra-high-performance liquid chromatography (LC)/tandem mass spectrometry methods for the determination of imatinib in plasma from patients with chronic myeloid leukemia.
  
  
  METHODS
  The plasma for analysis by both methods was deproteinated by methanol containing d8-imatinib. The separation was achieved on a 1.7 μm C18 column with a linear gradient (4 mM ammonium formiate and acetonitrile, pH 3.2). FIA was performed at flow rate of 0.03 mL/min (0.1% formic acid in methanol). Multiple reaction monitoring mode on the tandem mass spectrometer (API 4000, AB Sciex) in positive ESI were used for detection.
  
  
  RESULTS
  The total analysis times were 3.2 (LC) and 0.75 min (FIA). Both methods were successfully validated and applied to the plasma patients samples. The limits of quantification were 4.1 and 30.8 ng/mL; imprecisions were less than 5.7% and recovery ranged between 93 and 105%, for the LC and FIA, respectively. The methods revealed an agreement with a mean difference of 1.46 ng/mL (SD 28.95 ng/mL).
  
  
  CONCLUSIONS
  The high-throughput methods that were developed are suitable for the therapeutic drug monitoring of imatinib in plasma. They can be used in routine clinical practice.
authors: Laboratory of Inherited Metabolic Disorders, University Hospital and Palacký University in Olomouc, I.P. Pavlova 6, CZ 775 20 Olomouc, Czech Republic.
authors: Kateřina
authors: K
authors: Mičová
authors: David
authors: D
authors: Friedecký
authors: Edgar
authors: E
authors: Faber
authors: Adriana
authors: A
authors: Polýnková
authors: Tomáš
authors: T
authors: Adam
mesh_terms: D001549:Benzamides; D001774:Blood Chemical Analysis / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D017022:Flow Injection Analysis / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy; D010879:Piperazines / Q000097:blood* / Q000627:therapeutic use; D011743:Pyrimidines / Q000097:blood* / Q000627:therapeutic use; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate